148 related articles for article (PubMed ID: 22098006)
1. Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature.
Brewer JD; Hoverson Schott AR; Roenigk RK
Int J Dermatol; 2011 Dec; 50(12):1555-9. PubMed ID: 22098006
[TBL] [Abstract][Full Text] [Related]
2. Etanercept combined with methotrexate for high-need psoriasis.
Driessen RJ; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
[TBL] [Abstract][Full Text] [Related]
3. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis.
Ly L; Czarnecki D
Br J Dermatol; 2007 Nov; 157(5):1076-8. PubMed ID: 17854370
[No Abstract] [Full Text] [Related]
4. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
5. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
6. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
Pariser DM; Leonardi CL; Gordon K; Gottlieb AB; Tyring S; Papp KA; Li J; Baumgartner SW
J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
8. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
9. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years.
Lebwohl M; Blum R; Berkowitz E; Kim D; Zitnik R; Osteen C; Wallis WJ
Arch Dermatol; 2005 Jul; 141(7):861-4. PubMed ID: 16027301
[TBL] [Abstract][Full Text] [Related]
10. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy.
Fryrear RS; Wiggins AK; Sangueza O; Yosipovitch G
J Am Acad Dermatol; 2004 Dec; 51(6):1026. PubMed ID: 15583608
[No Abstract] [Full Text] [Related]
11. Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
Smith EC; Riddle C; Menter MA; Lebwohl M
Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874
[TBL] [Abstract][Full Text] [Related]
12. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
Haitz KA; Kalb RE
J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
[TBL] [Abstract][Full Text] [Related]
13. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma.
Chong BF; Wong HK
Clin Exp Dermatol; 2009 Jul; 34(5):e11-3. PubMed ID: 19040508
[TBL] [Abstract][Full Text] [Related]
14. Etanercept: effectiveness and safety data of a retrospective study.
Antoniou C; Vergou T; Dessinioti C; Stratigos AJ; Avgerinou G; Stavropoulos P; Katsambas A
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1113-5. PubMed ID: 20673305
[No Abstract] [Full Text] [Related]
15. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy.
Smith KJ; Skelton HG
J Am Acad Dermatol; 2001 Dec; 45(6):953-6. PubMed ID: 11712048
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of etanercept as monotherapy for psoriasis.
Gottlieb AB; Matheson RT; Lowe N; Krueger GG; Kang S; Goffe BS; Gaspari AA; Ling M; Weinstein GD; Nayak A; Gordon KB; Zitnik R
Arch Dermatol; 2003 Dec; 139(12):1627-32; discussion 1632. PubMed ID: 14676082
[TBL] [Abstract][Full Text] [Related]
17. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
18. Etanercept in psoriasis treatment.
Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
[TBL] [Abstract][Full Text] [Related]
19. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.
Antoniou C; Dessinioti C; Stratigos A; Avgerinou G; Stavropoulos P; Katsambas A
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):979-82. PubMed ID: 19470056
[No Abstract] [Full Text] [Related]
20. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
